Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Combined in Vitro and Ex Vivo Dose Finding Study

• Conditions: I80; Phlebitis and thrombophlebitis

• Registration Number: DRKS00007577
• Lead Sponsor: Charité Campus Virchow-Klinikum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-10-10
• Study Start: 2015-01-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Healthy Adult Subjects:
no preexisting coagulation disorder, no preesisting diseases, agree to participate, no intake of anticoagulant drugs within 7 days before Study paritcipation;
Patients after elective Hip- or Kneereplacement receive Apixaban (Eliquis®) for thromboprophylaxis, agree to participate, no preexisting coagulation disorders, normal kidney function, no intake of anticoagulant drugs except Apixaban, agree to participate

Exclusion Criteria

Healthy Adult Subjects:
Treatment as a Patient in Charite Hospital, pregnant or breastfeeding, refusal of participation, preexisting coagulation disorder, intake anticoagulant drug permanently or during the study, insufficient German language comprehension, a legal or governmental custodian, participate in a AMG trial;
Patients: refusal of participation, pregnant or breastfeeding, preexisting coagulation disorder, intake anticoagulant drug permanently or during the study except Apixaban (Eliquis®), renal insuffiency, insufficient German language comprehension, a legal or governmental custodian, participate in a AMG trial

Study & Design

• Study Type: observational
• Study Design: Not specified